Supplemental Process Can Aid in Assessing Value of Rare Disease Treatments

July 25, 2020


A study looking at the ways in which different countries handle appraisal and reimbursement processes for rare disease treatments (RDTs) revealed that implementing supplemental processes can aid in patient and physician decision making.

Is Home Care Going Mainstream in the United States?

June 22, 2020


Technology has made it easier to deliver health care in the home in recent years, but the financing models have not caught up just yet.

What Are the Barriers to Choosing Wisely in Hematology Care?

June 19, 2020


The American Society of Hematology has adopted 10 of the recommendations from Choosing Wisely to encourage more high-value care, but barriers to adoption remain.

CMS Issues Rules to Promote Value-Based Contracting, Pay for High-Cost Therapies in Medicaid

June 18, 2020


Administrator Seema Verma said the proposal would create opportunities "for drug manufacturers to have skin in the game through payment arrangements that challenge them to put their money where their mouth is."

Linking Opportunity Costs and Value Assessments for State and Commercial Payers

May 20, 2020


When deciding which treatments to cover, states and commercial payers must wrestle with opportunity costs as new therapeutics come to market. A panel at Virtual ISPOR 2020 discussed some of the factors that go into those decisions.

Virtual ISPOR Panel to Examine Next Steps in Value Assessment

May 18, 2020


Two of the panelists appearing during the Virtual ISPOR 2020 meeting preview what's needed in improving value assessment: Lou Garrison, PhD, of the University of Washington, and Leah Howard, JD, of the National Psoriasis Foundation.

NAACOS: ACOs Saved Medicare $3.5 Billion From 2013 to 2017

December 04, 2019


Accountable care organizations (ACOs) have saved Medicare a total of $3.53 billion from 2013 to 2017, or $755 million after shared savings were paid out, according to a new report from the National Association of ACOs (NAACOS).

Value Considerations Should Begin Very Early in the New Drug Development Life Cycle

October 31, 2019


Value needs to be considered early in the development life cycle of a therapy and should be continued throughout, even into the postlaunch space using real-world studies, according to a presentation on value-based services and their life cycles at the AMCP Nexus 2019 meeting.